Nanoscope Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies to cure genetic diseases that cause vision impairment and blindness. These diseases include Retinitis Pigmentosa, Dry Age-related Macular Degeneration (AMD), and Stargardt Disease. The company is developing a proprietary platform technology, using light-sensitive molecules, called Multi-Characteristic Opsins (MCO), and light-assisted gene delivery for giving sight to the millions of blind individuals.

The company's lead product, MCO-010, has been granted Orphan Drug and Fast Track designation by the US FDA for both retinitis pigmentosa (RP) and Stargardt disease.